The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Pharma powerhouse names Cecile Guegan interim finance chief
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
